- Medical Imaging Techniques and Applications
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Prostate Cancer Treatment and Research
- Medical Imaging and Pathology Studies
- Protease and Inhibitor Mechanisms
- Lymphoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Cardiac Structural Anomalies and Repair
- Hematological disorders and diagnostics
- Thyroid Cancer Diagnosis and Treatment
- MRI in cancer diagnosis
- Lung Cancer Treatments and Mutations
- Cardiac tumors and thrombi
- Lung Cancer Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer Diagnosis and Treatment
- Cell Adhesion Molecules Research
- Neuropeptides and Animal Physiology
- Ear and Head Tumors
- Bone health and treatments
- Prostate Cancer Diagnosis and Treatment
Acıbadem University
2024-2025
Education Training And Research
2018-2024
Sağlık Bilimleri Üniversitesi
2018-2024
University of Health Sciences
2019-2024
Acıbadem Adana Hospital
2024
University of Health Sciences Antigua
2019-2024
University of Health Science
2022-2023
Ministry of Health
2022
Committee on Publication Ethics
2022
Bağcılar Eğitim ve Araştırma Hastanesi
2022
Abstract BACKGROUND. This study was designed to investigate the fluorine‐18 fluorodeoxyglucose (FDG)‐positron emission tomography (PET) imaging characteristics of triple‐negative (estrogen receptor‐negative [ER−]/progesterone [PR−]/HER2‐negative [HER2−]) breast carcinoma and compare results with ER+/PR+/HER2− carcinomas, which usually carry a favorable prognosis. METHODS. Patients newly diagnosed who had undergone dual‐time‐point FDG‐PET before any therapeutic intervention were identified as...
Cancer-associated fibroblasts, which are densely found in tumor tissue, express high levels of fibroblast activation protein (FAP), and FAP inhibitors (FAPIs) labeled with radionuclides can be used the diagnosis treatment cancer. In this study, role 68Ga-DOTA-FAPI-04 PET/CT imaging primary, metastatic, recurrent cancers was investigated.A total 42 patients (16 females, 26 males; mean age, 58.5 years; range, 31-84 years) 22 different types malignant diseases were included study. performed 1...
In this prospective study, PET findings of 18 F-FDG PET/CT in breast cancer staging were compared with 68 Ga-FAP inhibitor (FAPI) 04 selected cases relatively low uptake the primary tumor or suspected nodal distant metastases.Twenty-four women a median age 45 years (range, 36-67 years) who underwent initial for Ga-FAPI-04 imaging within same week. SUV max and quantities tumors locoregional metastatic lesions recorded from both images, these data statistically.The histological subtypes 11...
This study aimed to compare the diagnostic capabilities of 18 F-FDG PET/CT and 68 Ga-FAPI-04 imaging in staging gastric carcinoma, exploring impact on treatment planning its prognostic significance.
The purpose of this prospective study was to investigate whether correlations exist between 18F-FDG uptake primary breast cancer lesions and predictive prognostic factors such as estrogen receptor (ER), progesterone (PR), C-erbB-2 (C-erbB-2R) states.Before undergoing partial or total mastectomy, 213 patients with newly diagnosed underwent PET (5.2 MBq/kg body weight). maximum standardized value (SUV) the lesion measured in each patient. Standard immunohistochemistry performed on a surgical...
Conventional imaging modalities are inadequate to evaluate locoregional extension of prostate cancer (PCa). The aim the current retrospective study was investigate diagnostic efficacy Gallium-68 prostate-specific membrane antigen-11 (Ga-68 PSMA-11) positron emission tomography/computed tomography (PET/CT) and multiparametric magnetic resonance (mp-MRI) for staging preoperative PCa patients with correlating histopathology.Twenty-four histologically proven underwent both Ga-68 PSMA-11 PET/CT...
Purpose Prostate-specific membrane antigen (PSMA)–targeted PET/CT is a well-established imaging method in prostate cancer (PC) for both staging and restaging, also theranostic applications. An alternative crucial 15% PSMA-negative cases. We aimed to investigate the contribution of 68 Ga-DOTA-FAPI-04 PC imaging. Patients Methods Thirty-six patients diagnosed with were included. underwent Ga-PSMA within 1 week. In group, primary tumor uptake values compared, correlations done histopathological...
Positron Emission Tomography/Computed Tomography (PET/CT) combines metabolic and anatomical information improving the precision accuracy of oncological diagnostics. The standardized uptake value (SUV) measures tumor metabolism, yet its is influenced by partial volume effect (PVE), impacting small lesion detection. This study aims to refine PVE corrections for lesions using an in-house customized, special anthropomorphic phantom. Scans this phantom which contained spheres different sizes were...
Gastrin-releasing peptide receptor (GRPR) is a promising agent for imaging and development of theranostic radioligands in estrogen (ER)-positive luminal type breast cancer (BC) may show expression not only primary malignant lesions but also lymph node metastases distant organ metastases. We would like to present lesion diagnosed as benign apocrine metaplasia 45-year-old woman with BC, which was negative 68 Ga-DOTA-Bombesin PET-CT false positive 18 F-FDG imaging, within the scope ongoing study.
A 67-year-old man with prostate adenocarcinoma underwent Ga-labeled prostate-specific membrane antigen (PSMA) ligand PET/CT for restaging due to a rising level. Local recurrence in the prostatic region and metastasis left iliac bone were detected showing high PSMA expression. mass lesion was seen orbitofrontal Ga uptake. The successive MRI confirmed that consistent meningioma.
Recent years have seen the start of treatment metastatic castration-resistant prostate cancer with prostate-specific membrane antigen (PSMA)–targeted radioligand therapy (PRLT), especially <sup>177</sup>Lu-PSMA-617. However, PRLT has side effects on salivary glands that limit safety treatment. The current study aimed to show effect external cooling ice packs <sup>177</sup>Lu-PSMA-617 uptake by parotid (PGs). <b>Methods:</b> included 19 patients (mean age, 72.9 y) who had been referred for...
Introduction Prostate-specific membrane antigen (PSMA) ligand PET/CT is an emerging modality to detect the metastatic disease, especially in intermediate- and high-risk prostate cancer (PCa). In this study, we analyzed contribution of 68 Ga-PSMA-11 staging therapy management newly diagnosed PCa. Materials Methods A total 78 patients with biopsy-proven PCa who were referred for primary retrospectively analyzed. The divided into risk groups according D'Amico stratification criteria. All had...
Purpose: The aim of this study was to assess the role PET in management patients with primary malignant salivary gland (SG) tumor. Material and Methods: Sixty-one FDG studies 48 (median age 58, range 28–89 years, 20 female, 28 male) who were diagnosed SG tumors retrospectively analyzed. Thirteen referred for initial diagnosis staging while there a suspicion recurrence and/or metastatic disease during follow-up period. Results: On examinations 13 on presentation, 12 showed increased uptake...
Fever of unknown origin (FUO) is generally defined as a fever greater than 38.3°C on several occasions during period longer 3 weeks for which the etiology behind cannot be diagnosed at end least 1 week hospital stay. Conventional diagnostic methods are still not adequate to reveal underlying reason in approximately 50% patients with FUO. In certain diagnosis, three major categories infections, malignancies, and noninfectious inflammatory diseases. Fluoro-18-fluoro-2-deoxy-D-glucose (FDG)...
Objective In this study, primary tumors' fluorine-18-fluorodeoxyglucose (18F-FDG) uptake in luminal A, B, triple-negative, and human epidermal growth factor receptor type-2 subtypes of breast cancer was evaluated. addition, the relationship between tumor maximum standardized value (SUVmax) presence distant metastasis axillary involvement Patients methods Whole-body 18F-FDG PET/computed tomography (CT) imaging 493 patients (mean age; 54.6±13.2 years) diagnosed with were analyzed...
We present the findings of 68Ga-FAPI-4 PET/CT and 18F-FDG a metastatic malignant melanoma patient with osteoarthritis. A 65-year-old woman history uveal was referred to for restaging after enucleation chemotherapy. imaging showed high radiotracer uptake in liver metastases; additionally mild due osteoarthritis observed both knees. However, although lower lesions, it more prominent knee joints compared 18F-FDG.
Fibroblast activation protein (FAP) is expressed as a pro-inflammatory agent from fibrous tissue in liver cirrhosis and the tumor microenvironment. Cirrhosis last stage of any chronic disease, natural course progression asymptomatic phase to symptomatic decompensated with development ascites. Although various clinical features suggest patients non-invasive methods should follow approach before definitive diagnosis. Herein, we present three cases fibroblast inhibitor (FAPI) uptake demonstrate...
O Ob bj je ec ct ti iv ve e: Fever of unknown origin (FUO) is a challenge for the physician and needs use clinical, laboratory, imaging studies also invasive and/or non-invasive interventions to detect etiology.The aim present study was assess role FDG PET/CT in determining etiology patients with FUO.Material Methods: Twenty-four (median age 52, range 5-77 years, 6 female, 18 male) who were diagnosed FUO retrospectively analyzed this study.Before studies, none them had definitive reason...
Aim of study is to compare the results Gallium-68-prostate-specific membrane antigen ( 68 Ga-PSMA) and 18 F-fluorodeoxyglucose F-FDG) positron emission tomography(PET)/computed tomography (CT), evaluate correlation between PET findings level PSMA, Claudin (Clau) 1, 4, 7 receptors obtained by immunohistochemical (IHC) analysis, determine potential predictive prognostic values in TNBC.Forty-seven lesions 42 subjects diagnosed TNBC both underwent PET/CT scan for preoperative staging/restaging...
Abstract We present an 87-year-old man diagnosed with prostate cancer and neuroendocrine differentiation, posttherapy results to consecutive 177 Lu–prostate-specific membrane antigen Lu-DOTATATE. Despite hormonal therapy chemoradiotherapy, the patient progressed rapidly, multiple liver bone metastases showed regression after Lu-DOTATATE treatment. Prostate differentiation is resistant treatments; however, treatment combination of may be promising.